PA5-86135

antibody from Invitrogen Antibodies

Targeting: TFDP1 DILC, Dp-1, DP1, DRTF1

Western blot

Antibody data

Submit

Validation data

Product number: PA5-86135 - Provider product page
Provider: Invitrogen Antibodies
Product name: DP1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Reactivity: Human, Mouse, Rat
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

TFDP1 protein structure - PA5-86135 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 2 HGF induced MYCN transcription requires an intact E2F site. (A) A MYCN promoter-luciferase construct was transfected into HepG2 cells followed by treatment with HGF. The cells were harvested at indicated time points and luciferase activities were normalized by GFP fluorescence and protein concentration. (B) IPA analysis of upstream regulators of MYCN. (C) Primary murine hepatocytes were transfected with indicated siRNAs. Knockdown efficiencies were verified by Western. (D,E) Primary murine hepatocytes were transfected with indicated siRNAs followed by treatment with HGF for 24 h. MYCN expression was examined by qPCR and Western. (F) WT or mutant MYCN promoter-luciferase construct was transfected into HepG2 cells followed by treatment with HGF for 24 h. Luciferase activities were normalized by GFP fluorescence and protein concentration. Data are expressed as mean +- standard deviation (SD). * p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 4 BRG1 interacts with E2F5-TFDP1 to activate MYCN transcription. (A) Immunoprecipitation was performed with anti-BRG1 or IgG using primary murine hepatocyte lysates. (B) Primary murine hepatocytes were treated with HGF and harvested at indicated time points. ChIP assays were performed with anti-BRG1, anti-E2F5, anti-TFDP1, or IgG. Upper panel, a scheme of the MYCN promoter highlighting the positions of the two proximal E2F sites and the ChIP primers. TSS, transcription start site. (C-E) Primary murine hepatocytes were transfected with indicated siRNAs followed by treatment with HGF. ChIP assay was performed with anti-BRG1, anti-E2F5, and anti-TFDP1. (F-L) Primary hepatocytes were isolated from WT and BRG1 CKO mice followed by treatment with HGF. ChIP assays were performed with anti-E2F5, anti-TFDP1, anti-acetyl H3, anti-trimethyl H3K4, anti-RNA polymerase II, anti-p300, and anti-KMT2A. Data are expressed as mean +- standard deviation (SD). * p < 0.05 (one-way ANOVA with post hoc Scheffe test).